Clinical Trials Logo
  1. Home
  2. Eosinophilic Gastroenteritis
  3. NCT05251909

Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) — HUDSON GI  

Eosinophilic Gastroenteritis Clinical Trial

Official title:
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)

Clinical Trial Summary

This is a 3-part study. Part A is randomized, double-blinded, placebo-controlled and includes patients with eosinophilic gastritis and/or duodenal-only disease. After completing Part A, participants can continue to Part C - open-label benralizumab treatment period. Following the decision to close enrollment, patients in both Part A and Part C will be given the option to proceed to 6-months of open-label benralizumab treatment in Part D.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05251909
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 3
Start date January 18, 2022
Completion date February 13, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03320369 - Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis N/A
Completed NCT00148603 - Montelukast in the Treatment of Duodenal Eosinophilia N/A
Completed NCT03664960 - An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis Phase 2
Completed NCT00267475 - Data Bank for Eosinophilic Disorders N/A
Completed NCT04856891 - A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis Phase 3
Active, not recruiting NCT03678545 - Dupilumab in Eosinophilic Gastritis Phase 2
Terminated NCT01814059 - Sirolimus for Eosinophil-Associated Gastrointestinal Disorders Phase 1
Active, not recruiting NCT05214768 - A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis Phase 3
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT03496571 - A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Phase 2
Recruiting NCT02523118 - OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
Completed NCT05439772 - Examining the Effect of Ondansetron on Bowel Prep Success Phase 4
Completed NCT00266565 - Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Phase 1/Phase 2
Recruiting NCT05199532 - Eosinophilic Gastrointestinal Disorders Registry
Terminated NCT01212016 - Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders N/A
Completed NCT02897271 - Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort